Tyrosine kinase inhibitorFDA-approvedInvestigational
Gilteritinib
How it works
Blocks the FMS-like tyrosine kinase 3 (FLT3) protein, which is involved in the growth and survival of cancer cells in certain types of leukemia.
Cancer types
Leukemia— FLT3-ITD-positive AML
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 10 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing SNDX-5613 and Gilteritinib for Leukemia Treatment | Leukemia | phase-1 | — | Source → |
| New Trial for Acute Myeloid Leukemia Patients Explores Alternative Treatments | Leukemia | phase-3 | — | Source → |
| Gilteritinib May Help Overcome Resistance to Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Testing a New Treatment for Relapsed or Refractory AML with FLT3 Mutation | Leukemia | phase-3 | — | Source → |
| Testing Gilteritinib for Advanced ALK-positive Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Gilteritinib Therapy After Transplantation for High-Risk AML Patients | Leukemia | meta-analysis | 1- and 2-year overall survival rates ranged from 72.3% to 100% and 55.8% to 60.0%, respectively. | Source → |
| Gilteritinib May Help Treat Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| New Cancer Treatment Shows Promise with Low Heart Damage | Leukemia | lab-study | — | Source → |
| Rare Eye Condition Linked to Cancer Treatment | Leukemia | observational | — | Source → |
| Combining Metformin and Gilteritinib May Improve Leukemia Treatment | Leukemia | lab-study | Metformin plus gilteritinib (low dose) dramatically suppressed leukemia progression and prolonged survival in FLT3-ITD AML mouse models. | Source → |
| Rare Skin Reaction Linked to Leukemia Treatment | Leukemia | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.